PDF(Pubmed)
Abstract：
UNASSIGNED: Adjuvant treatment with aromatase inhibitors (AI) in oestrogen receptor-positive and/or progesterone receptor-positive breast cancer (BC) has been shown to increase overall survival. However, arthralgias and myalgias are common adverse effects in patients treated with AI.
UNASSIGNED: To evaluate the frequency and characteristics of arthralgias and myalgias in patients with early BC-treated adjuvantly with AI in the Mastology Unit of the Oncology Service of the Hospital de Clínicas and the Departmental Hospital of Soriano.
UNASSIGNED: A prospective, cross-sectional and descriptive study was performed. A questionnaire was administered to patients to assess the presence and characteristics of arthralgias and myalgias associated with AI.
UNASSIGNED: \'Age\' was described with measures of central tendency and dispersion. Qualitative variables were presented in absolute and relative frequencies. Logistic models were used to evaluate the association between patient characteristics, tumour characteristics, treatment characteristics and the presence of pain. Results were presented by odds ratio and p-value, using R software (version 4.1.2) with a significance threshold of 5%.
UNASSIGNED: 83 patients were included, with a median age of 69 years. 75.9% presented arthralgias and/or myalgias related to treatment, with an average intensity of 5-7. 80.9% received non-steroidal anti-inflammatory drugs (NSAIDs), achieving satisfactory analgesia. The presence of arthralgias and myalgias was significantly associated with age and time since the last menstrual period (LMP), being more frequent in patients older than 50 years and those with more than 5 years since the LMP.
UNASSIGNED: Approximately 70% of the patients presented arthralgias or myalgias. These findings suggest a possible role of oestrogen withdrawal in its mechanism of development. Multidisciplinary and translational research is crucial to evaluate the ethology and therapeutic options for patients with AI-related arthralgia.
UNASSIGNED: To evaluate the frequency and characteristics of arthralgias and myalgias in patients with early BC-treated adjuvantly with AI in the Mastology Unit of the Oncology Service of the Hospital de Clínicas and the Departmental Hospital of Soriano.
UNASSIGNED: A prospective, cross-sectional and descriptive study was performed. A questionnaire was administered to patients to assess the presence and characteristics of arthralgias and myalgias associated with AI.
UNASSIGNED: \'Age\' was described with measures of central tendency and dispersion. Qualitative variables were presented in absolute and relative frequencies. Logistic models were used to evaluate the association between patient characteristics, tumour characteristics, treatment characteristics and the presence of pain. Results were presented by odds ratio and p-value, using R software (version 4.1.2) with a significance threshold of 5%.
UNASSIGNED: 83 patients were included, with a median age of 69 years. 75.9% presented arthralgias and/or myalgias related to treatment, with an average intensity of 5-7. 80.9% received non-steroidal anti-inflammatory drugs (NSAIDs), achieving satisfactory analgesia. The presence of arthralgias and myalgias was significantly associated with age and time since the last menstrual period (LMP), being more frequent in patients older than 50 years and those with more than 5 years since the LMP.
UNASSIGNED: Approximately 70% of the patients presented arthralgias or myalgias. These findings suggest a possible role of oestrogen withdrawal in its mechanism of development. Multidisciplinary and translational research is crucial to evaluate the ethology and therapeutic options for patients with AI-related arthralgia.
摘要：
■在雌激素受体阳性和/或孕激素受体阳性的乳腺癌（BC）中，芳香化酶抑制剂（AI）的辅助治疗已被证明可以增加总体生存率。然而,关节痛和肌痛是AI治疗患者的常见不良反应。
■评估在Clínicas医院肿瘤科和Soriano部门医院肿瘤学部门中接受AI辅助治疗的早期BC患者的关节痛和肌痛的频率和特征。
■预期，我们进行了横断面和描述性研究.对患者进行问卷调查，以评估与AI相关的关节痛和肌痛的存在和特征。
■\'年龄\'用集中趋势和分散的度量来描述。定性变量以绝对频率和相对频率表示。Logistic模型用于评估患者特征之间的关联，肿瘤特征，治疗特点和疼痛的存在。结果由赔率比和p值表示，使用R软件（4.1.2版），显著性阈值为5%。
■83名患者被纳入，中位年龄为69岁。75.9%出现与治疗相关的关节痛和/或肌痛，平均强度为5-7。80.9%的人接受了非甾体抗炎药(NSAIDs)，达到满意的镇痛。关节痛和肌痛的存在与上次月经期（LMP）以来的年龄和时间显着相关，在50岁以上和LMP后超过5年的患者中更常见。
■大约70%的患者出现关节痛或肌痛。这些发现表明雌激素戒断可能在其发育机制中发挥作用。多学科和转化研究对于评估AI相关关节痛患者的行为学和治疗选择至关重要。
■评估在Clínicas医院肿瘤科和Soriano部门医院肿瘤学部门中接受AI辅助治疗的早期BC患者的关节痛和肌痛的频率和特征。
■预期，我们进行了横断面和描述性研究.对患者进行问卷调查，以评估与AI相关的关节痛和肌痛的存在和特征。
■\'年龄\'用集中趋势和分散的度量来描述。定性变量以绝对频率和相对频率表示。Logistic模型用于评估患者特征之间的关联，肿瘤特征，治疗特点和疼痛的存在。结果由赔率比和p值表示，使用R软件（4.1.2版），显著性阈值为5%。
■83名患者被纳入，中位年龄为69岁。75.9%出现与治疗相关的关节痛和/或肌痛，平均强度为5-7。80.9%的人接受了非甾体抗炎药(NSAIDs)，达到满意的镇痛。关节痛和肌痛的存在与上次月经期（LMP）以来的年龄和时间显着相关，在50岁以上和LMP后超过5年的患者中更常见。
■大约70%的患者出现关节痛或肌痛。这些发现表明雌激素戒断可能在其发育机制中发挥作用。多学科和转化研究对于评估AI相关关节痛患者的行为学和治疗选择至关重要。
